Back to discover
Drug
Nicotinamide Mononucleotide
In clinical developmentEmerging researchEarly-to-mid development
Also known as NICOTINAMIDE RIBOTIDE.
1
Research papers
1
Active clinical trials
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this drug.
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors in Healthy Young and Older Adults
Clinical trial2025-05-06Results expected Q4 2026 · ClinicalTrials.gov
The therapeutic perspective of NAD<sup>+</sup> precursors in age-related diseases.
Research2024-02-02Biochemical and biophysical research communications
Clinical trial2021-09-09Completed · ClinicalTrials.gov
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Canonical name
Nicotinamide Mononucleotide
Aliases & brands
NICOTINAMIDE RIBOTIDE
RxNorm CUI
2262276
ChEMBL ID
CHEMBL610238
UNII
2KG6QX4W0V
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY2
registered trials across all phases
LATEST COMPLETION 2021
1
Active studies
1
Recruiting
1
Late-stage (III+)
1
Completed
PHASE DISTRIBUTIONn = 2
Phase 11Phase N / A1
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes2
Dietary Supplements1NAD1
Journals, researchers & institutions
Top journals
- Biochemical and biophysical research communications1
Leading researchers
- Iqbal T1
- Nakagawa T1
Leading institutions
free-text, unnormalised
- University of Toyama1
References & data sources
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials